VRI to use Proteome Systems platform to develop diagnostics
27 November, 2002 by Melissa TrudingerVRI BioMedical and Proteome Systems have signed a non-binding heads of agreement for a collaboration to develop some of VRI's diagnostic tests as point-of-care applications using Proteome Systems' proprietary diagnostic test platform.
High-profile agreements give Ambri global clout
26 November, 2002 by Pete YoungSydney biosensor specialist Ambri is leveraging newly-forged ties with two high-profile US corporates to negotiate lucrative R&D contracts with the US military.
New report pulls back the curtain on SA biotech
26 November, 2002 by Melissa TrudingerThe secrets of the South Australian bioscience sector have been revealed in a survey released last week by BioInnovation SA, the government-supported biotech industry development team.
Peplin swaps skin with Allergan
26 November, 2002 by Graeme O'NeillBrisbane's Peplin Biotech and California-based dermatology products specialist Allergan have swapped skin on a deal to bring Peplin's promising anti-cancer compound PEP005 to the skin-cancer market.
Healthy deal-flow sparks pSivida share surge
25 November, 2002 by Pete YoungA sudden surge in pSivida's share price this month focused attention on the biomaterials company's growing string of promising alliances.
Prima successful in fundraising
22 November, 2002 by Melissa TrudingerPrima Biomed has become the latest biotech company to successfully raise additional funds through a private placement to institutional and professional investors.
The future of beef is bioactive
22 November, 2002 by Graeme O'NeillFinicky beefeater Jack Sprat and his lipophilic wife would be amazed at what the meat industry is doing these days with the bits neither would eat.
GroPep debt-free by the end of 2002, company chairman says
22 November, 2002 by Melissa TrudingerAdelaide-based biotech company GroPep pre-empted the complaints of its shareholders at its annual general meeting yesterday, with chairman Richard England noting at the beginning of his speech that the year was the worst in the company's history.
Green light for EpiTan IIb trial
21 November, 2002 by Melissa TrudingerEpiTan has received approval from the ethics committee at the Royal Adelaide Hospital to conduct part of its phase IIb clinical trial there for its melanin-producing drug Melanotan.
Flinders Bio to expand business
21 November, 2002 by Melissa TrudingerFlinders University spin-off Flinders Bioremediation is continuing to expand its business operations despite the recent loss of founder and managing director Dr Nick McClure, who passed away in September.
Starpharma nets third US dendrimer patent
21 November, 2002 by Melissa TrudingerStarpharma has been granted a third broad US patent for its dendrimer technology, covering applications for anti-microbial and anti-parasitic compositions.
Biotech stripped raw
20 November, 2002 by Graeme O'NeillListen carefully and one can almost hear new biotechnology companies sprouting from Australia's bioscience research landscape.
Changes on Metabolic board
20 November, 2002 by Melissa TrudingerProf Peter Darvall has resigned from his board position at Melbourne drug discovery company Metabolic Pharmaceuticals due to his commitments as vice-chancellor of Monash University.
Metabolic begins fourth trial of obesity drug
18 November, 2002 by Melissa TrudingerMelbourne-based Metabolic Pharmaceuticals has begun a Phase IIA clinical trial for its obesity drug AOD9604 to investigate safety of daily dosing in preparation for the Phase IIB weight reduction study scheduled for next year.
The jungle telegraph: how plants communicate
18 November, 2002 by Graeme O'NeillHow does a soybean plant's leaves communicate with its roots, hidden beneath the ground?
